Masimo Corporation (MASI - Free Report) recently announced the findings of a study published in the Turkish Journal of Emergency Medicine, wherein researchers explored the utility of noninvasive, continuous Masimo Pleth Variability Index (PVi) when it comes to monitoring volume status and changes in spontaneously breathing patients who are undergoing hemodialysis (HD). Per the findings, a strong correlation has been found between change in PVi and the volume of fluid removed.
Based on the positive outcome, PVi might offer clinicians useful information for monitoring the volume status in critically ill patients with spontaneous breathing.
It is worth mentioning that in the United States, PVi has clearance to be utilized as noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.
The latest favorable study outcome is likely to provide a boost to Masimo’s non-invasive patient monitoring solutions portfolio.
More on the Study
There have been more than 100 independent studies demonstrating the utility of PVi as an indicator of fluid responsiveness. For this particular study, researchers enrolled 60 adult patients with end-stage renal disease receiving routine HD — wherein fluid is removed simultaneously with the removal of waste solutes — and had a median of 3,500 cc of fluid removed during HD.
PVi was measured utilizing a Masimo pulse oximetry sensor attached to a Masimo Root monitor, before and after HD, while changes in PVi were compared to the amount of fluid removed during the session.
It is important to mention here that the reliability of PVi in estimating fluid responsiveness is variable and can be influenced by several patient, procedure and device-associated factors.
Market Prospects
Per a report by Market Data Forecast, the global fluid management systems market is projected to be worth $14.74 billion by 2026 from $11.12 billion in 2021, at a CAGR of 5.8% during the forecast period. Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s patient monitoring business profile.
Recent Developments
This month, the company announced the findings of a study published in the Journal of Pain & Relief wherein researchers explored the utility of Masimo Bridge in reducing postoperative opioid needs in patients undergoing kidney donor surgery. Bridge, an auricular field nerve stimulator, was found to be associated with significant reductions in opioid use and pain after surgery.
In July, the company announced robust second-quarter 2021 results where it recorded a strong rebound in sensor sales (on the back of steady expansion of monitoring in hospitals), along with robust order shipments.
The same month, Masimo announced the release of its latest and most advanced rainbow SET board, MX-7. The board has been engineered for integration into numerous multi-parameter monitors available with the company’s various original equipment manufacturing partners.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have gained 29% in the past year compared with the industry’s growth of 14.9%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , Envista Holdings Corporation (NVST - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein’s long-term earnings growth rate is estimated at 13.9%.
Envista Holdings’ long-term earnings growth rate is estimated at 27.4%.
Merit Medical’s long-term earnings growth rate is projected at 13.6%.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Masimo Corporation (MASI - Free Report) recently announced the findings of a study published in the Turkish Journal of Emergency Medicine, wherein researchers explored the utility of noninvasive, continuous Masimo Pleth Variability Index (PVi) when it comes to monitoring volume status and changes in spontaneously breathing patients who are undergoing hemodialysis (HD). Per the findings, a strong correlation has been found between change in PVi and the volume of fluid removed.
Based on the positive outcome, PVi might offer clinicians useful information for monitoring the volume status in critically ill patients with spontaneous breathing.
It is worth mentioning that in the United States, PVi has clearance to be utilized as noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.
The latest favorable study outcome is likely to provide a boost to Masimo’s non-invasive patient monitoring solutions portfolio.
More on the Study
There have been more than 100 independent studies demonstrating the utility of PVi as an indicator of fluid responsiveness. For this particular study, researchers enrolled 60 adult patients with end-stage renal disease receiving routine HD — wherein fluid is removed simultaneously with the removal of waste solutes — and had a median of 3,500 cc of fluid removed during HD.
PVi was measured utilizing a Masimo pulse oximetry sensor attached to a Masimo Root monitor, before and after HD, while changes in PVi were compared to the amount of fluid removed during the session.
It is important to mention here that the reliability of PVi in estimating fluid responsiveness is variable and can be influenced by several patient, procedure and device-associated factors.
Market Prospects
Per a report by Market Data Forecast, the global fluid management systems market is projected to be worth $14.74 billion by 2026 from $11.12 billion in 2021, at a CAGR of 5.8% during the forecast period. Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s patient monitoring business profile.
Recent Developments
This month, the company announced the findings of a study published in the Journal of Pain & Relief wherein researchers explored the utility of Masimo Bridge in reducing postoperative opioid needs in patients undergoing kidney donor surgery. Bridge, an auricular field nerve stimulator, was found to be associated with significant reductions in opioid use and pain after surgery.
In July, the company announced robust second-quarter 2021 results where it recorded a strong rebound in sensor sales (on the back of steady expansion of monitoring in hospitals), along with robust order shipments.
The same month, Masimo announced the release of its latest and most advanced rainbow SET board, MX-7. The board has been engineered for integration into numerous multi-parameter monitors available with the company’s various original equipment manufacturing partners.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have gained 29% in the past year compared with the industry’s growth of 14.9%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , Envista Holdings Corporation (NVST - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein’s long-term earnings growth rate is estimated at 13.9%.
Envista Holdings’ long-term earnings growth rate is estimated at 27.4%.
Merit Medical’s long-term earnings growth rate is projected at 13.6%.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on HSIC - FREE
Get the latest research report on MASI - FREE
Get the latest research report on MMSI - FREE
Get the latest research report on NVST - FREE